Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma

Hye Sun Shin, Seungup Kim, Junyong Park, doyoung kim, KwangHyub Han, Chae Yoon Chon, Oidov Baatarkhuu, SangHoon Ahn

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and Aim: Little information is available about the antiviral efficacy of lamivudine (LAM) and entecavir (ETV) in patients with hepatitis B virus (HBV)-related advanced hepatocellular carcinoma (HCC). Thus, we compared the antiviral efficacy of LAM and ETV in these patients. Methods: The medical records of 134 antiviral therapy-naïve patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] Tumor, Nodes, and Metastases [TNM] stages III-IV) treated between January 2005 and September 2009 were reviewed. After HCC diagnosis, 87 (64.9%) and 47 (35.1%) patients received LAM and ETV, respectively. Results: The mean age of patients (115 men, 19 women) was 53years. Sixty-five (48.5%) and 69 (51.5%) patients had TNM stages III and IV HCC, respectively. Treatment outcomes during follow-up, including virologic, biochemical, and serologic responses and appearance of antiviral resistance, were similar in the LAM and ETV groups (all P>0.05). Multivariate analysis identified Child-Pugh class, α-fetoprotein, and TNM stage as independent predictors of overall survival (all P<0.05). Antiviral agent type (LAM vs ETV) did not influence overall survival (median 9.6months in LAM vs 13.6months in ETV group; P=0.493). HCC treatment was not interrupted due to HBV flare up in any patient. Conclusions: The antiviral efficacy of LAM and ETV was similar and the type of antiviral agent did not influence overall survival in patients with HBV-related advanced HCC. Thus, LAM, which is less expensive than ETV in Korea, might be sufficient to control HBV in these patients.

Original languageEnglish
Pages (from-to)1528-1534
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume27
Issue number9
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Lamivudine
Hepatitis B virus
Antiviral Agents
Hepatocellular Carcinoma
Neoplasm Metastasis
Survival
Neoplasms
Fetal Proteins
entecavir
Korea
Medical Records
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{20816c1ae799451089710bbb20e7d211,
title = "Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma",
abstract = "Background and Aim: Little information is available about the antiviral efficacy of lamivudine (LAM) and entecavir (ETV) in patients with hepatitis B virus (HBV)-related advanced hepatocellular carcinoma (HCC). Thus, we compared the antiviral efficacy of LAM and ETV in these patients. Methods: The medical records of 134 antiviral therapy-na{\"i}ve patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] Tumor, Nodes, and Metastases [TNM] stages III-IV) treated between January 2005 and September 2009 were reviewed. After HCC diagnosis, 87 (64.9{\%}) and 47 (35.1{\%}) patients received LAM and ETV, respectively. Results: The mean age of patients (115 men, 19 women) was 53years. Sixty-five (48.5{\%}) and 69 (51.5{\%}) patients had TNM stages III and IV HCC, respectively. Treatment outcomes during follow-up, including virologic, biochemical, and serologic responses and appearance of antiviral resistance, were similar in the LAM and ETV groups (all P>0.05). Multivariate analysis identified Child-Pugh class, α-fetoprotein, and TNM stage as independent predictors of overall survival (all P<0.05). Antiviral agent type (LAM vs ETV) did not influence overall survival (median 9.6months in LAM vs 13.6months in ETV group; P=0.493). HCC treatment was not interrupted due to HBV flare up in any patient. Conclusions: The antiviral efficacy of LAM and ETV was similar and the type of antiviral agent did not influence overall survival in patients with HBV-related advanced HCC. Thus, LAM, which is less expensive than ETV in Korea, might be sufficient to control HBV in these patients.",
author = "Shin, {Hye Sun} and Seungup Kim and Junyong Park and doyoung kim and KwangHyub Han and Chon, {Chae Yoon} and Oidov Baatarkhuu and SangHoon Ahn",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2012.07145.x",
language = "English",
volume = "27",
pages = "1528--1534",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma

AU - Shin, Hye Sun

AU - Kim, Seungup

AU - Park, Junyong

AU - kim, doyoung

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - Baatarkhuu, Oidov

AU - Ahn, SangHoon

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background and Aim: Little information is available about the antiviral efficacy of lamivudine (LAM) and entecavir (ETV) in patients with hepatitis B virus (HBV)-related advanced hepatocellular carcinoma (HCC). Thus, we compared the antiviral efficacy of LAM and ETV in these patients. Methods: The medical records of 134 antiviral therapy-naïve patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] Tumor, Nodes, and Metastases [TNM] stages III-IV) treated between January 2005 and September 2009 were reviewed. After HCC diagnosis, 87 (64.9%) and 47 (35.1%) patients received LAM and ETV, respectively. Results: The mean age of patients (115 men, 19 women) was 53years. Sixty-five (48.5%) and 69 (51.5%) patients had TNM stages III and IV HCC, respectively. Treatment outcomes during follow-up, including virologic, biochemical, and serologic responses and appearance of antiviral resistance, were similar in the LAM and ETV groups (all P>0.05). Multivariate analysis identified Child-Pugh class, α-fetoprotein, and TNM stage as independent predictors of overall survival (all P<0.05). Antiviral agent type (LAM vs ETV) did not influence overall survival (median 9.6months in LAM vs 13.6months in ETV group; P=0.493). HCC treatment was not interrupted due to HBV flare up in any patient. Conclusions: The antiviral efficacy of LAM and ETV was similar and the type of antiviral agent did not influence overall survival in patients with HBV-related advanced HCC. Thus, LAM, which is less expensive than ETV in Korea, might be sufficient to control HBV in these patients.

AB - Background and Aim: Little information is available about the antiviral efficacy of lamivudine (LAM) and entecavir (ETV) in patients with hepatitis B virus (HBV)-related advanced hepatocellular carcinoma (HCC). Thus, we compared the antiviral efficacy of LAM and ETV in these patients. Methods: The medical records of 134 antiviral therapy-naïve patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] Tumor, Nodes, and Metastases [TNM] stages III-IV) treated between January 2005 and September 2009 were reviewed. After HCC diagnosis, 87 (64.9%) and 47 (35.1%) patients received LAM and ETV, respectively. Results: The mean age of patients (115 men, 19 women) was 53years. Sixty-five (48.5%) and 69 (51.5%) patients had TNM stages III and IV HCC, respectively. Treatment outcomes during follow-up, including virologic, biochemical, and serologic responses and appearance of antiviral resistance, were similar in the LAM and ETV groups (all P>0.05). Multivariate analysis identified Child-Pugh class, α-fetoprotein, and TNM stage as independent predictors of overall survival (all P<0.05). Antiviral agent type (LAM vs ETV) did not influence overall survival (median 9.6months in LAM vs 13.6months in ETV group; P=0.493). HCC treatment was not interrupted due to HBV flare up in any patient. Conclusions: The antiviral efficacy of LAM and ETV was similar and the type of antiviral agent did not influence overall survival in patients with HBV-related advanced HCC. Thus, LAM, which is less expensive than ETV in Korea, might be sufficient to control HBV in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84865377664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865377664&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2012.07145.x

DO - 10.1111/j.1440-1746.2012.07145.x

M3 - Article

C2 - 22497450

AN - SCOPUS:84865377664

VL - 27

SP - 1528

EP - 1534

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 9

ER -